UBS raised the firm’s price target on Guardant Health (GH) to $70 from $65 and keeps a Buy rating on the shares. Guardant Health reported a quarterly beat, with guidance raised amid better volume and average selling price, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health price target raised to $65 from $60 at BTIG
- Guardant Health price target raised to $65 from $60 at Canaccord
- Guardant Health’s Strong Growth Potential and Upward Trajectory Justifies Buy Rating
- Guardant Health: Strong Financial Performance and Growth Potential Justify Buy Rating
- Guardant Health: Strong Financial Performance and Strategic Positioning Drive Buy Rating